Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Drug Information and Pharmacotherapy
DI-039
PRELIMINARY STUDY TO ESTABLISH A NEW LINK BETWEEN HOSPITAL AND RETAIL PHARMACISTS TO FOLLOW UP PATIENTS TREATED WITH VITAMIN K ANTAGONISTS
DI-038
APPROPRIATE USE OF ANTI-DEMENTIA DRUGS IN THE ELDERLY: PRESCRIPTION PRACTICE EVALUATION IN NURSING HOMES
DI-037
TOXIC EPIDERMAL NECROLYSIS PROBABLY DUE TO CHEMOTHERAPY: A CASE REPORT
DI-036
INTRAVITREAL AFLIBERCEPT IN REFRACTORY AGE-RELATED MACULAR DEGENERATION
DI-035
SHOULD WE MAKE PATIENTS AND NURSES AWARE OF THEIR DRUG ADMINISTRATION PROBLEMS AND TRAINING NEEDS?
DI-032
ANTIRETROVIRAL THERAPY, ADHERENCE AND QUALITY OF LIFE IN OLDER HIV-PATIENTS WITH MODERATE-HIGH CARDIOVASCULAR RISK
DI-031
ANALYSIS OF ADVERSE DRUG REACTIONS REPORTED IN A UNIVERSITY HOSPITAL FOR PREVENTABILITY
DI-029
QUALITY OF INFORMATION ON MALE FERTILITY IN THE SUMMARY OF PRODUCT CHARACTERISTICS - CAUSE FOR CONCERN
DI-028
OFF-LABEL USE: A DESCRIPTIVE RETROSPECTIVE ANALYSIS.
DI-027
PEMETREXED USE IN PATIENTS WITH STAGE IV LUNG ADENOCARCINOMA WHO UNDERGO THYMIDYLATE SYNTHASE LEVEL INVESTIGATION
DI-026
IMPACT OF A TARGETED POLICY ON INTRAVENOUS OXYCODONE AND MORPHINE CONSUMPTION
DI-025
DIMETHYLFUMARATE FOR THE TREATMENT OF MULTIPLE SCLEROSIS : DOSING REGIMEN AND SAFETY DATA.
DI-024
OFF-LABEL USE OF GABAPENTIN AND PREGABALIN IN A TERTIARY HOSPITAL
DI-023
EFFECT OF DIFFERENT ANTIFUGAL EYE DROPS ON HUMAN CORNEAL CELLS IN VITRO
DI-022
NEW CHANCES IN MULTIPLE SCLEROSIS TREATMENT: SUSTAINED-RELEASE FAMPRIDINE
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
next ›
last »
Follow Us